Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

BACKGROUND: Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4865968/
https://ncbi.nlm.nih.gov/pubmed/27124339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.107
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares